用于预测完整脑转移瘤单次立体定向放射手术后放射性坏死的递归分割分析的发展。

IF 3.2 2区 医学 Q2 CLINICAL NEUROLOGY
Anirudh Bommireddy, Zachary S Mayo, Chandana A Reddy, Cole Billena, Erik M Davies, Robin W Davis, Erin S Murphy, John H Suh, Ehsan H Balagamwala, Timothy A Chan, Jennifer S Yu, Gene H Barnett, Lilyana Angelov, Alireza M Mohammadi, Glen H J Stevens, Matthew Grabowski, David M Peereboom, Samuel T Chao
{"title":"用于预测完整脑转移瘤单次立体定向放射手术后放射性坏死的递归分割分析的发展。","authors":"Anirudh Bommireddy, Zachary S Mayo, Chandana A Reddy, Cole Billena, Erik M Davies, Robin W Davis, Erin S Murphy, John H Suh, Ehsan H Balagamwala, Timothy A Chan, Jennifer S Yu, Gene H Barnett, Lilyana Angelov, Alireza M Mohammadi, Glen H J Stevens, Matthew Grabowski, David M Peereboom, Samuel T Chao","doi":"10.1007/s11060-025-05062-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose/objective: </strong>Radiation necrosis (RN) is a potential complication after stereotactic radiosurgery (SRS) for brain metastases. This study develops a recursive partitioning analysis (RPA) to identify patients at risk for RN following SRS.</p><p><strong>Methods: </strong>Patients who underwent single-fraction SRS for intact brain metastases at a single institution from 2017 to 2021 were identified. Cox regression identified factors associated with RN, and variables with p < 0.1 were included in the RPA. Patients with staged SRS, incomplete records, or less than 3 months of follow-up were excluded.</p><p><strong>Results: </strong>The study included 170 patients with 919 lesions, with median follow-up of 9 months. Primary disease sites were non-small cell lung cancer (NSCLC, 49%), breast cancer (12%), melanoma (11%), renal cancer (6%), and others (22%). Median prescription dose was 24 Gy, and median maximum lesion dimension (MLD) was 0.7 cm. RN occurred in 110 (12.2%) lesions, of which 32 (3.5%) were symptomatic, at median of 4.9 months after SRS. Variables for RPA included primary disease site, tumor location, MLD, prior SRS, number of SRS targets, dosimetry, prior hemorrhage, and concurrent systemic therapy. RPA identified four groups: Group 1 (MLD ≤ 0.8 cm, non-breast/NSCLC/renal), Group 2 (MLD ≤ 0.8 cm, breast/NSCLC/renal), Group 3 (MLD > 0.8 cm, no post-SRS hemorrhage), and Group 4 (MLD > 0.8 cm, post-SRS hemorrhage). Two-year RN free survival was 99% (Group 1), 89% (Group 2), 70% (Group 3), and 52% (Group 4).</p><p><strong>Conclusion: </strong>This is the first RPA model for RN after single-fraction SRS, which may aid in risk assessment and distinguishing RN from tumor progression.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of a recursive partitioning analysis for prediction of radiation necrosis following single-fraction stereotactic radiosurgery for intact brain metastases.\",\"authors\":\"Anirudh Bommireddy, Zachary S Mayo, Chandana A Reddy, Cole Billena, Erik M Davies, Robin W Davis, Erin S Murphy, John H Suh, Ehsan H Balagamwala, Timothy A Chan, Jennifer S Yu, Gene H Barnett, Lilyana Angelov, Alireza M Mohammadi, Glen H J Stevens, Matthew Grabowski, David M Peereboom, Samuel T Chao\",\"doi\":\"10.1007/s11060-025-05062-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose/objective: </strong>Radiation necrosis (RN) is a potential complication after stereotactic radiosurgery (SRS) for brain metastases. This study develops a recursive partitioning analysis (RPA) to identify patients at risk for RN following SRS.</p><p><strong>Methods: </strong>Patients who underwent single-fraction SRS for intact brain metastases at a single institution from 2017 to 2021 were identified. Cox regression identified factors associated with RN, and variables with p < 0.1 were included in the RPA. Patients with staged SRS, incomplete records, or less than 3 months of follow-up were excluded.</p><p><strong>Results: </strong>The study included 170 patients with 919 lesions, with median follow-up of 9 months. Primary disease sites were non-small cell lung cancer (NSCLC, 49%), breast cancer (12%), melanoma (11%), renal cancer (6%), and others (22%). Median prescription dose was 24 Gy, and median maximum lesion dimension (MLD) was 0.7 cm. RN occurred in 110 (12.2%) lesions, of which 32 (3.5%) were symptomatic, at median of 4.9 months after SRS. Variables for RPA included primary disease site, tumor location, MLD, prior SRS, number of SRS targets, dosimetry, prior hemorrhage, and concurrent systemic therapy. RPA identified four groups: Group 1 (MLD ≤ 0.8 cm, non-breast/NSCLC/renal), Group 2 (MLD ≤ 0.8 cm, breast/NSCLC/renal), Group 3 (MLD > 0.8 cm, no post-SRS hemorrhage), and Group 4 (MLD > 0.8 cm, post-SRS hemorrhage). Two-year RN free survival was 99% (Group 1), 89% (Group 2), 70% (Group 3), and 52% (Group 4).</p><p><strong>Conclusion: </strong>This is the first RPA model for RN after single-fraction SRS, which may aid in risk assessment and distinguishing RN from tumor progression.</p>\",\"PeriodicalId\":16425,\"journal\":{\"name\":\"Journal of Neuro-Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-05-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neuro-Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11060-025-05062-5\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-025-05062-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的/目的:放射坏死(RN)是立体定向放射手术(SRS)治疗脑转移瘤后的潜在并发症。本研究开发了递归划分分析(RPA)来识别SRS后有RN风险的患者。方法:从2017年到2021年,在单一机构对完整脑转移患者进行了单次SRS。Cox回归确定了与RN相关的因素和p变量。结果:研究纳入170例患者,共919个病变,中位随访9个月。原发疾病部位为非小细胞肺癌(NSCLC, 49%)、乳腺癌(12%)、黑色素瘤(11%)、肾癌(6%)和其他(22%)。中位处方剂量为24 Gy,中位最大病变尺寸(MLD)为0.7 cm。在SRS后的中位时间为4.9个月,110个(12.2%)病灶发生RN,其中32个(3.5%)有症状。RPA的变量包括原发疾病部位、肿瘤位置、MLD、既往SRS、SRS靶点数量、剂量学、既往出血和同时的全身治疗。RPA确定了四组:1组(MLD≤0.8 cm,非乳腺/NSCLC/肾),2组(MLD≤0.8 cm,乳腺/NSCLC/肾),3组(MLD > 0.8 cm,无srs后出血),4组(MLD > 0.8 cm, srs后出血)。两年无RN生存率分别为99%(1组)、89%(2组)、70%(3组)和52%(4组)。结论:这是单组分SRS后RN的第一个RPA模型,可能有助于风险评估和区分RN与肿瘤进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Development of a recursive partitioning analysis for prediction of radiation necrosis following single-fraction stereotactic radiosurgery for intact brain metastases.

Purpose/objective: Radiation necrosis (RN) is a potential complication after stereotactic radiosurgery (SRS) for brain metastases. This study develops a recursive partitioning analysis (RPA) to identify patients at risk for RN following SRS.

Methods: Patients who underwent single-fraction SRS for intact brain metastases at a single institution from 2017 to 2021 were identified. Cox regression identified factors associated with RN, and variables with p < 0.1 were included in the RPA. Patients with staged SRS, incomplete records, or less than 3 months of follow-up were excluded.

Results: The study included 170 patients with 919 lesions, with median follow-up of 9 months. Primary disease sites were non-small cell lung cancer (NSCLC, 49%), breast cancer (12%), melanoma (11%), renal cancer (6%), and others (22%). Median prescription dose was 24 Gy, and median maximum lesion dimension (MLD) was 0.7 cm. RN occurred in 110 (12.2%) lesions, of which 32 (3.5%) were symptomatic, at median of 4.9 months after SRS. Variables for RPA included primary disease site, tumor location, MLD, prior SRS, number of SRS targets, dosimetry, prior hemorrhage, and concurrent systemic therapy. RPA identified four groups: Group 1 (MLD ≤ 0.8 cm, non-breast/NSCLC/renal), Group 2 (MLD ≤ 0.8 cm, breast/NSCLC/renal), Group 3 (MLD > 0.8 cm, no post-SRS hemorrhage), and Group 4 (MLD > 0.8 cm, post-SRS hemorrhage). Two-year RN free survival was 99% (Group 1), 89% (Group 2), 70% (Group 3), and 52% (Group 4).

Conclusion: This is the first RPA model for RN after single-fraction SRS, which may aid in risk assessment and distinguishing RN from tumor progression.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Neuro-Oncology
Journal of Neuro-Oncology 医学-临床神经学
CiteScore
6.60
自引率
7.70%
发文量
277
审稿时长
3.3 months
期刊介绍: The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信